Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate
| Autor: | Benedikta S. Haflidadóttir, Albertas Ulys, Kristina Stuopelyte, Daniel C. Danila, Hans Lilja, Arnas Bakavicius, Juozas R. Lazutka, Chintan Patel, Riina Minna Väänänen, Sonata Jarmalaite, Rasa Sabaliauskaite, Feliksas Jankevičius, Tapio Visakorpi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.drug_class Urology Abiraterone Acetate 030232 urology & nephrology Antineoplastic Agents Drug resistance Castration resistant Article 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Internal medicine Biomarkers Tumor medicine Humans Protein Isoforms Neoplasm Prospective Studies Liquid biopsy Whole blood business.industry Abiraterone acetate Middle Aged medicine.disease Androgen Progression-Free Survival Prostatic Neoplasms Castration-Resistant chemistry Drug Resistance Neoplasm Receptors Androgen Case-Control Studies Multivariate Analysis RNA business Follow-Up Studies |
| Zdroj: | J Urol |
| ISSN: | 1527-3792 0022-5347 |
| Popis: | Reliable molecular diagnostic tools are still unavailable for making informed treatment decisions and monitoring the response in patients with castration resistant prostate cancer. We evaluated the significance of whole blood circulating androgen receptor transcripts of full length (AR-FL) and splice variants (AR-V1, AR-V3 and AR-V7) as biomarkers of abiraterone acetate treatment resistance in patients with castration resistant prostate cancer.After retrospective analysis in 112 prostate specimens AR-FL, AR-V1, AR-V3 and AR-V7 were evaluated in 185 serial blood samples, prospectively collected from 102 patients with castration resistant prostate cancer before and during abiraterone acetate therapy via reverse transcription quantitative polymerase chain reaction.AR-FL was present in all samples while AR-V1, AR-V3, AR-V7 and at least 1 of them was detected in 17%, 55%, 65% and 81% of castration resistant prostate cancer blood samples, respectively. The highest amount of AR-V1 was found in blood of patients whose response time was short and medium in comparison to extended. Patients with a higher level of AR-FL and/or AR-V1 had the shortest progression-free survival and overall survival (p0.0001).Blood circulating AR-FL or AR-V1 can serve as blood based biomarkers for identification of the primary resistance to abiraterone acetate and the tool to monitor de novo resistance development during abiraterone acetate treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|